CStone Announces the First-in-Class Registrational Clinical Tr...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SUZHOU, China, May 28, 2021 /PRNewswire-AsiaNet/ -- -Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully improve progression-free survival (PFS) in patients with stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent or sequen...
Authors: LATEST ASIANET NEWS RELEASES